
Fabihenz

Favipiravir Tablets 200 mg and 400 mg



Fabihenz



Favipiravir Tablets 200 mg and 400 mg

Description:

Favipiravir is a pyrazine carboxamide derivative (6-fluoro-3-hydroxy-2-pyrazinecarboxamide). It is a broad-spectrum antiviral drug- effective against various subtypes and strains of influenza and other RNA viruses.

Composition:

FABIHENZ-200 Tablet Each Film coated tablet contains: Favipiravir......200 mg FABIHENZ-400 Tablet Each Film coated tablet contains: Favipiravir......400 mg

Indication:

For the management of adults in mild to moderate COVID-19 disease under restricted emergency use.

Mechanism of Action:

Favipiravir (prodrug) is a purine base analog that is converted to active favipiravir ribofuranosyl-5B-triphosphate (favipiravir-RTP) by intracellular phosphoribosylation. It is a selective and potent inhibitor of RNA-dependent RNA polymerase (RdRp) of RNA viruses. Favipiravir is incorporated into the nascent viral RNA by error prone viral RdRp, which leads to chain termination and viral mutagenesis. Favipiravir, an oral, broad spectrum RdRp inhibitor and has an established and well-characterized safety profile.

Dosage and Administration:

The recommended dosage of favipiravir for adults is 1800 mg orally twice daily on 1st day followed by 800 mg orally twice daily, up to maximum of 14 days.

Use in the Elderly

Since the elderly often have reduced physiological functions, favipiravir should be administered with care to them by monitoring their general conditions.

Pediatric Use

Favipiravir has not been administered to children.

Note:

Use only as directed by a physician.

Contraindication:

- Women known or suspected to be pregnant (Early embryonic deaths and teratogenicity have been observed in animal studies) and Lactating women
- Hypersensitivity to the active substance
- Severe hepatic and Renal impairment

Presentation:

FABIHENZ-200/400: Its available as blister pack of 10 tablets

La Renon Healthcare Private Limited